Author: Matthew Nelson|| Date Published: January 28, 2021
Eli Lilly and Co. (NYSE: LLY) has secured a $625 million contract modification to supply 500,000 more doses of the company’s COVID-19 monoclonal antibody drug to the U.S. Army.
Army Contracting Command obligated the full amount of the modification using fiscal 2021 Coronavirus Aid, Relief and Economic Security Act funds, the Department of Defense said Wednesday.
In November, the Food and Drug Administration granted emergency use authorization for Lilly’s LY-CoV555 antibody drug as a treatment for patients 12 years and older who have mild to moderate COVID-19 and at risk of developing severe coronavirus infection.
Bamlanivimab is intended to be administered via intravenous infusion, the company noted.
Understanding how organizations can prepare for a Cybersecurity Maturity Model Certification, or CMMC, assessment often starts with structured road maps…
The Department of Transportation is undergoing rapid transformation under Transportation Secretary Sean Duffy. Since stepping into the role in January 2025, Duffy…
The Army Contracting Command-Aberdeen Proving Ground and the Capability Program Executive Enterprise Software and Service, formerly Program Executive Office Enterprise,…
LMI has been awarded a $100 million Small Business Innovation Research Phase III indefinite-delivery/indefinite-quantity contract to support life cycle logistics and…
